18
|
Insulin Like Growth Factor-1 (IGF-1)
|
Protein
|
Mice
|
Downregulated in SPI (soy protein isolate) diet: [Control: (223 ±61ng/ml; SPI Diet: 349 ±40 ng/ml )
|
Prognostic
|
PCa Mice fed Control Diet Vs PCa Mice fed soy protein isolate Diet
|
p<0.05
|
Serum
|
10460196
|
28
|
Insulin
|
Protein
|
Humans
|
Upregulated in High Risk Group
|
Prognostic
|
High vs (Medium and Low) Risk
|
p= 0.05
|
Serum
|
11757030
|
32
|
Triiodothyronine
|
Protein
|
Humans
|
Upregulated in Prostate Cancer (Control: 72 ±24.9; PCa: 83.9 ±18.1)
|
Diagnostic
|
Normal Prostate vs Localised Prostate Cancer
|
p = 0.048
|
Serum
|
12441933
|
33
|
Triiodothyronine
|
Protein
|
Humans
|
Upregulated in Prostate Cancer (PCa: 83.9 ±18.1 vs BPH: 94.4±12.3)
|
Diagnostic
|
Localised Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p = 0.013
|
Serum
|
12441933
|
34
|
Triiodothyronine
|
Protein
|
Humans
|
Upregulated in High Risk Group
|
Prognostic
|
High vs Moderate Risk Group
|
p=0.041
|
Serum
|
12497024
|
35
|
Triiodothyronine
|
Protein
|
Humans
|
Upregulated in High Risk Group
|
Prognostic
|
High vs Low Risk Group
|
p=0.013
|
Serum
|
12497024
|
36
|
Lycopene
|
Protein
|
Humans
|
Downregulated (41% fold)
|
Diagnostic
|
Normal vs Cancerous
|
p<0.05
|
Serum
|
12497123
|
94
|
E-cadherin
|
Protein
|
Humans
|
Upregulated in Localised PCa (BPH: 7.26; Localised PCa: 9.46)
|
Diagnostic
|
Benign Prostatic Hyperplasia (BPH) Vs Localised PCa
|
p=0.011
|
Serum
|
15870707
|
95
|
E-cadherin
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: (Localised PCa: 9.46; Metastatic PCa: 27.49)
|
Prognostic
|
Localised PCa Vs Metastatic PCa
|
p<0.001
|
Serum
|
15870707
|
96
|
E-cadherin
|
Protein
|
Humans
|
Iincreased risk of late biochemical failure with high expression
|
Prognostic
|
Biochemical Faliure Vs No Biochemical Faliure
|
p<0.05
|
Serum
|
15870707
|
101
|
bromo domain containing protein 2 (BRD2),+eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)+ribosomal protein L22 (RPL22)+ribosomal protein L13a (RPL13a)+17 other autoantibodies
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Serum
|
16177248
|
107
|
18 proteins with Mass (Da) M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031+ M5265 +M15878 + M16003 + M16068
|
Protein
|
Humans
|
Downregulated in PCa: [M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031Upregulated in PCa: [M5265 +M15878 + M16003 + M16068]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.01
|
Serum
|
16372118
|
108
|
FPA
|
Protein
|
Humans
|
Downregulated (0.58 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.000108
|
Serum
|
16395409
|
109
|
Fibrogen alpha
|
Protein
|
Humans
|
Downregulated (0.33 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.00000000000763
|
Serum
|
16395409
|
110
|
inter-α-trypsin inhibitor heavy chain H4 (ITIH4)
|
Protein
|
Humans
|
Upregulated (121 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.0000108
|
Serum
|
16395409
|
111
|
Clusterin Beta
|
Protein
|
Humans
|
Upregulated (251 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.00000000481
|
Serum
|
16395409
|
112
|
factor X111a
|
Protein
|
Humans
|
Upregulated (2.84 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.0000000143
|
Serum
|
16395409
|
120
|
ICTP
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Serum
|
16434583
|
121
|
BSAP
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Serum
|
16434583
|
122
|
TRAP5b
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Serum
|
16434583
|
131
|
PTGS2
|
Other
|
Humans
|
Upregulated in PCa [(Mean Values) PCa: 85.95; BPH: 25.26]
|
Diagnostic
|
Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa)
|
P<0.0001
|
Serum
|
17764114
|
132
|
PTGS2
|
Other
|
Humans
|
Upregulated in PCa [(Mean Values) PCa: 85.95; Healthy Individuals: 10.88]
|
Diagnostic
|
Prostate Cancer (PCa) Vs Healthy Individuals
|
P<0.0001
|
Serum
|
17764114
|
133
|
PTGS2
|
Other
|
Humans
|
Increased expression with increase in relapse
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p = 0.0395
|
Serum
|
17764114
|
137
|
β-2-Microglobulin
|
Protein
|
Humans
|
Upregulated in Metastatic Prostate Cancer (Controls: 1.9± 0.6; Metastatic Castrate PCa: 2.7 ± 1.1)
|
Diagnostic
|
Controls Vs Metastatic Castrate Prostate Cancer
|
p<0.05
|
Serum
|
17404077
|
220
|
VEGF (Vascular Endothelial Growth Factor)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.01
|
Serum
|
17932343
|
221
|
Resistin
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.04
|
Serum
|
17932343
|
222
|
IL-1Ra (Interleukin 1Ra)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.03
|
Serum
|
17932343
|
223
|
MMP-3 (Matrix Metalloproteinase-3)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.01
|
Serum
|
17932343
|
224
|
PAI-1(active) (Plasminogen Activator Inhibitor)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.01
|
Serum
|
17932343
|
225
|
AFP (α- Fetoprotein)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.02
|
Serum
|
17932343
|
226
|
Kallikrein-8
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.02
|
Serum
|
17932343
|
227
|
PSA
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.0001
|
Serum
|
17932343
|
228
|
G-CSF (Granulocyte Colony-Stimulating Factor)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.005
|
Serum
|
17932343
|
239
|
Anterior Gradient 2 Homolog AGR2
|
Protein
|
Humans
|
Upregulatated in PCa (3.8 fold)
|
Diagnostic
|
Normal Vs Prostate Cancer
|
p=0.0021
|
Serum
|
18061988
|
240
|
YKL- 40
|
Protein
|
Humans
|
Upregulated in PCa (PPC: 188.01 Vs BPH: 73.54 ± 9.25)
|
Diagnostic
|
Benign Prostatic Hyperplasia vs Primary Prostate Cancer
|
p<0.001
|
Serum
|
18190830
|
241
|
Chitotriosidase
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 91.33 ± 8.32 Vs BPH: 69.72 ±8.69)
|
Diagnostic
|
Normal (Control) Vs Cancer (High Gleason Grade)
|
p<0.05
|
Serum
|
18190830
|
242
|
CXCL12
|
Protein
|
Humans
|
Upregulated in Biopsy Positive Patients
|
Diagnostic
|
Biopsy Negative Patients And Biopsy Positive Patients for Prostate Cancer
|
p=0.05
|
Serum
|
18196514
|
284
|
%[-2]proPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.001
|
Serum
|
18550118
|
285
|
PSA+BPSA+%fPSA+%[-2] proPSA+[-2]proPSA/BPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p<0.05
|
Serum
|
18550118
|
286
|
%fPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.008
|
Serum
|
18550118
|
410
|
Methylation Status of RARB2
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCa stage I-III VS PCa Stage IV
|
p=0.027
|
Serum
|
19131636
|
411
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCA stage I-III VS PCA Stage IV
|
p=0.019
|
Serum
|
19131636
|
412
|
Methylation Status of GSTP1+RARB2
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCA stage I-III VS PCA Stage IV
|
p=0.019
|
Serum
|
19131636
|
413
|
PSA +C4a lacking the C-terminal arginine (C4a des-Arg) + N-terminal fragment of PCI
|
Protein
|
Humans
|
Upregulated in PCa: [C4a lacking the C-terminal arginine (C4a des-Arg)];Downregulated in PCa: [N-terminal fragment of PCI]
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Training: p=0.012 Testing: p=0.011
|
Serum
|
19157448
|
458
|
Prostate specific antigen (PSA), Prostate Specific Membrane Antigen (PSMA), Platelet Factor-4 (PF-4), and Interleukin-6 (IL-6)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Female Controls
|
NA
|
Serum
|
19775154
|
462
|
Hepatocyte Growth Factor (HGF)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(18.9%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p<0.001
|
Serum
|
19542190
|
463
|
Vascular Endothelial Growth Factor (VEGF)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(9.9%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.032
|
Serum
|
19542190
|
464
|
Insulin Like Growth Factor (IGF-I)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(10.4%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.012
|
Serum
|
19542190
|
465
|
IGF Binding Protein-3 (IGFBP-3)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(11%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.024
|
Serum
|
19542190
|
466
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(7.9%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.009
|
Serum
|
19542190
|
467
|
IGF-I/IGFBP-3
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(3.4%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.028
|
Serum
|
19542190
|
478
|
Clusterin and Clusterin Density
|
Protein
|
Humans
|
Upregulated: Clusterin [(BPH: 94.2 ± 38.7) Vs (PCA: 137.2 ± 36.6 )]; Clusterin Density [(BPH: 3.2 ± 2.2 ) Vs (PCA: 5.5 ± 2.6 )]
|
Diagnostic
|
Benign Prostatic Hyperplasia Vs Prostate Cancer
|
p<0.001
|
Serum
|
19854485
|
479
|
Clusterin & Clusterin Density
|
Protein
|
Humans
|
Upregulated: Clusterin [(No Metastasis 131.1 ± 32.1) Vs (Metastasis: 151.3 ± 34.6 )]; Clusterin Density [(No Metastasis: 5.1 ± 2.3 ) Vs (Metastasis: 6.2 ± 2.7 )]
|
Prognostic
|
No Metastasis Vs Metastasis
|
p<0.001
|
Serum
|
19854485
|
480
|
Clusterin Density
|
Protein
|
Humans
|
Upregulated: Clusterin Density [(ExtraProstatic 6.2 ± 2.4) Vs (Organ-confined disease: 5.4 ± 2.2 )];
|
Prognostic
|
Organ-confined disease Vs Extraprostatic disease
|
p=0.033
|
Serum
|
19854485
|
481
|
Clusterin Density
|
Protein
|
Humans
|
Decreased expression in Patients with Biochemical Recurrence free Survival
|
Prognostic
|
Biochemical Recurrence Free Survival Vs No Survial
|
p=0.034
|
Serum
|
19854485
|
482
|
PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p<0.05
|
Serum
|
20632177
|
483
|
MMP-2
|
Protein
|
Humans
|
Upregulated and Hypermethylated (PCa: 684.65 ± 129.36; Normal: 609.63 ± 172.58)
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p=0.038
|
Serum
|
20632177
|
484
|
PSA+MMP-2+ AMACR + Methylation Status of (GSTP1 or RASSF1A)
|
Protein + DNA
|
Humans
|
Upregulated and Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p=0.036
|
Urine and Serum
|
20632177
|
496
|
e-FABP5
|
Protein
|
Humans
|
Upregulated in LNM PCa
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.01
|
Serum
|
19894759
|
497
|
e-FABP5
|
Protein
|
Humans
|
Upregulated in Localised PCA
|
Diagnostic
|
Localized PCa and BPH
|
p<0.01
|
Serum
|
19894759
|
515
|
p2PSA ([-2]isoform of proenzyme prostate specific antigen)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Sample
|
p = 0.0006
|
Serum
|
20171670
|
516
|
%fPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Sample
|
p=0.02
|
Serum
|
20171670
|
517
|
prostate specific antigen
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Sample
|
NA
|
Serum
|
20171670
|
518
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Sample
|
NA
|
Serum
|
20171670
|
523
|
hsa-miR-375-4373027; hsa-miR-9*-4395342; hsa-miR-141-4373137; hsa-miR-516a-3p-4373183; hsa-miR-629-4395547; hsa-miR-203-4373095; hsa-miR-429-4373203; hsa-miR-618-4380996; hsa-miR-212-4373087; hsa-miR-21-4373090; hsa-miR-545-4395378; hsa-miR-218-4373081; hsa-miR-422a-4395408; hsa-miR-656-4380920; hsa-miR-655-4381015; hsa-miR-29c-4395171; hsa-miR-200b-4395362; hsa-miR-200c-4395411; hsa-miR-502-5p-4373227;
|
miRNA
|
Humans
|
Upregulated in Metastatis (Log Fold Change): hsa-miR-375-4373027 [-4.3]; hsa-miR-9*-4395342 [-3.8]; hsa-miR-141-4373137 [-4.5]; hsa-miR-516a-3p-4373183 [-3.9]; hsa-miR-629-4395547 [-2.1]; hsa-miR-203-4373095 [-2.5]; hsa-miR-429-4373203 [-3.4]; hsa-miR-618-4380996 [-3.7]; hsa-miR-212-4373087 [-2.6]; hsa-miR-21-4373090 [-1.8]; hsa-miR-545-4395378 [-2.3]; hsa-miR-218-4373081 [-2.8]; hsa-miR-422a-4395408 [-2.1]; hsa-miR-656-4380920 [-2.8]; hsa-miR-655-4381015 [-2.4]; hsa-miR-29c-4395171 [-1.7]; hsa-miR-200b-4395362 [-3.1]; hsa-miR-200c-4395411 [-1.8]; hsa-miR-502-5p-4373227 [-3.1];
|
Prognostic
|
Localised Vs Metastatic Prostate Cancer
|
p<0.0098
|
Serum
|
20473869
|
524
|
miRNA-375, miRNA-141 and miRNA-200b
|
miRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Pathoglical Stage pt3 vs pt2
|
p<0.05
|
Serum
|
20473869
|
525
|
miRNA-375, miRNA-141 and miRNA-200b
|
miRNA
|
Humans
|
Upregulated
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 7
|
p<0.05
|
Serum
|
20473869
|
526
|
miRNA-375
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Lymph Node Status: NO Vs N1
|
p<0.01
|
Serum
|
20473869
|
527
|
miRNA-141
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Lymph Node Status: NO Vs N1
|
p<0.05
|
Serum
|
20473869
|
528
|
miRNA-141
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Gleason Score >8 Vs Gleason Score 7
|
p<0.01
|
Serum
|
20473869
|
551
|
Total sialic acid
|
Metabolites
|
Humans
|
Upregulated (mg/dL): (Controls: 6.25±3.49) Vs (Prostate Cancer: 15.1±4.83)
|
Diagnostic
|
Control Vs Cancer
|
p<0.001
|
Serum
|
20973404
|
552
|
Total sialic acid
|
Metabolites
|
Humans
|
Upregulated (mg/dL): (BPH: 7.24±4.56) Vs (Prostate Cancer: 15.1±4.83)
|
Diagnostic
|
BPH Vs Cancer
|
p<0.001
|
Serum
|
20973404
|
553
|
Cathepsin D
|
Protein
|
Humans
|
Upregulated (pmol/mL): (Controls: 4.85±1.35) Vs (Prostate Cancer: 9.2±1.75)
|
Diagnostic
|
Control Vs Cancer
|
p<0.001
|
Serum
|
20973404
|
554
|
Cathepsin D
|
Protein
|
Humans
|
Upregulated (pmol/mL): (BPH: 5.11±1.17) Vs (Prostate Cancer: 9.2±1.75)
|
Diagnostic
|
BPH Vs Cancer
|
p<0.001
|
Serum
|
20973404
|
563
|
freePSA (free prostate specific antigen)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
564
|
[-2]proPSA ([-2]proenzyme prostate specific antigen)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
565
|
%fPSA (%free prostate specific antigen)
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
566
|
DKK1 (Dickkopf-1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
567
|
NEM (neuroendocrine marker)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
568
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
570
|
miR-874, -1274a, -1207-5p, -93, and -106a
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Healthy Vs Prostate Cancer
|
miR-874 p<0.00; miR-1274a p<0.001; miR-1207-5p p<0.001; miR-93 p<0.001; miR-106a p<0.001
|
Serum
|
21098088
|
571
|
miR- 223, -26b, -30c, and -24
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Healthy Vs Prostate Cancer
|
miR-30c p= 0.01; miR-26b p<0.001; miR-223 p<0.001; miR-24 p= 0.005;
|
Serum
|
21098088
|
572
|
miR-106a, miR-93 and -1274a; miR-451; miR-1207-5p; miR-874
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Healthy Vs High Risk (CAPRA>5)
|
miR-106a p<0.001, miR-93 p<0.001; miR-1274a p<0.001; miR-451 p= 0.02; miR-1207-5p p<0.001; miR-874 p= 0.003
|
Serum
|
21098088
|
573
|
miR-223; miR-24;
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Healthy Vs High Risk (CAPRA>5)
|
miR-223 p= 0.002; miR-24 p=0.02
|
Serum
|
21098088
|
574
|
Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
BPH vs Prostate Cancer
|
NA
|
Serum
|
21166384
|
575
|
Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H + Gluthathione peroxidase 3
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Gleason Score 5 vs Gleason Score 7
|
NA
|
Serum
|
21166384
|
576
|
Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1
|
Protein
|
Humans
|
Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1]
|
Prognostic
|
Organ Confined vs Non-Organ Confined
|
NA
|
Serum
|
21166384
|
577
|
Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3
|
Protein
|
Humans
|
Upregulated
|
Diagnostic
|
BPH vs Prostate Cancer
|
NA
|
Serum
|
21166384
|
578
|
Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H +Gluthathione peroxidase 3
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Gleason Score 5 vs Gleason Score 7
|
NA
|
Serum
|
21166384
|
579
|
Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1
|
Protein
|
Humans
|
Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1]
|
Prognostic
|
Organ Confined vs Non-Organ Confined
|
NA
|
Serum
|
21166384
|
626
|
fPSA
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.024
|
Serum
|
21482022
|
627
|
%fPSA
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.008
|
Serum
|
21482022
|
628
|
PSA Density
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.001
|
Serum
|
21482022
|
629
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p < 0.001
|
Serum
|
21482022
|
630
|
Prostat Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p < 0.001
|
Serum
|
21482022
|
631
|
Base Model (Age+ Prostate Volume + tPSA+ fPSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Controls
|
Not significant
|
Serum
|
21482022
|
632
|
Base Model + %p2PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p < 0.001
|
Serum
|
21482022
|
633
|
Base Model + phi
|
Protein
|
Humans
|
Upregulated in PCa (phi)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p < 0.001
|
Serum
|
21482022
|
634
|
NY-ESO-1 + XAGE-1b + SSX-2,4 + AMACR + p90 + LEDGF + PSA Index
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs BPH
|
LEDGF, p90, SSX-2, 4, XAGE-1b: p<0.001; NY-ESO-1: p=0.029; AMACR: NS
|
Serum
|
21504557
|
635
|
PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs BPH
|
p<0.05
|
Serum
|
21504557
|
653
|
Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score
|
Protein
|
Humans
|
Downregulated in Patients with Gleason Score Upgradation
|
Prognostic
|
Gleason Score Upgradation Vs No Gleason Score Upgradation
|
p = 0.024
|
Serum
|
21520165
|
654
|
Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score
|
Protein
|
Humans
|
Downregulated in Patients with Gleason Score Upgradation
|
Prognostic
|
Gleason Score Upgradation Vs No Gleason Score Upgradation
|
NA
|
Serum
|
21520165
|
682
|
thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival (12 months)
|
NA
|
Serum
|
21741162
|
683
|
thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival (24 months)
|
NA
|
Serum
|
21741162
|
684
|
PVRL1 (poliovirus receptor-related 1); PRG4 (proteoglycan 4); AP (alkaline phosphatase); FSTL1 (follistatin-like 1); Albumin; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1); ANPEP (alanyl (membrane) aminopeptidase); CRP (C-reactive protein); Hb (hemoglobin); CADM1a (cell adhesion molecule 1a); POSTN (periostin, osteoblast specific factor); CADM1b (cell adhesion molecule 1b); CP (ceruloplasmin); AZGP1 (alpha-2-glycoprotein 1, zinc-binding).
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
PVRL1 (poliovirus receptor-related 1) p= 0.002; CD10 p= 0.004; PRG4 (proteoglycan 4) p = 0.006; AP (alkaline phosphatase) p= 0.007; FSTL1 (follistatin-like 1) p= 0.01; Albumin p= 0.016; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1) p = 0.018; ANPEP (alanyl (membrane) aminopeptidase) p=0.02; CRP (C-reactive protein) p= 0.02; Hb (hemoglobin) p=0.022; CADM1a (cell adhesion molecule 1a) p =0.03; POSTN (periostin, osteoblast specific factor) p=0.034; CADM1b (cell adhesion molecule 1b) p=0.035; CP (ceruloplasmin) p =0.046; AZGP1 (alpha-2-glycoprotein 1, zinc-binding) p =0.046.
|
Serum
|
21741162
|
706
|
α2-macroglobulin (α2M)
|
Protein
|
Humans
|
Upregulated (Healthy: 151.7±25.30 Vs without α2M deficiency: 252.45±125.07)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.01
|
Serum
|
21894431
|
707
|
C-reactive protein (CRP)
|
Protein
|
Humans
|
Upregulated (Healthy: 109.58±89.66 Vs without α2M deficiency: 1534.6±1482.8)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.01
|
Serum
|
21894431
|
708
|
serum amyloid A (SAA)
|
Protein
|
Humans
|
Upregulated (Healthy: 9.96±4.16 Vs without α2M deficiency: 54.7±44.5)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.01
|
Serum
|
21894431
|
709
|
interleukin-6 (IL-6)
|
Protein
|
Humans
|
Upregulated (Healthy: 7.58±6.0 Vs without α2M deficiency: 46.50±40.65)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.01
|
Serum
|
21894431
|
710
|
α1 anti-chymotripsin (α1AT)
|
Protein
|
Humans
|
Upregulated (Healthy: 122±28.0 Vs without α2M deficiency: 293.76±68.51)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.05
|
Serum
|
21894431
|
711
|
α1 acid glycoprotein (α1AG)
|
Protein
|
Humans
|
Upregulated (Healthy: 67.5±25.5 Vs without α2M deficiency: 102±39.36)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.05
|
Serum
|
21894431
|
712
|
Ceruloplasmin (CP)
|
Protein
|
Humans
|
Upregulated (Healthy: 29.0±8.0 Vs without α2M deficiency: 37.74±10.93)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.05
|
Serum
|
21894431
|
713
|
α2-macroglobulin (α2M)
|
Protein
|
Humans
|
Downregulated with α2M deficiency (Without α2M deficiency: 252.45±125.07 Vs with α2M deficiency: 12.75±5.60)
|
Prognostic
|
PCa patients without α2M deficiency vs. PCa patients with α2M deficiency
|
p<0.01
|
Serum
|
21894431
|
714
|
C-reactive protein (CRP)
|
Protein
|
Humans
|
Downregulated with α2M deficiency (without α2M deficiency: 1534.6±1482.8 Vs with α2M deficiency: 173±90.3)
|
Prognostic
|
PCa patients without α2M deficiency vs. PCa patients with α2M deficiency
|
p<0.01
|
Serum
|
21894431
|
715
|
serum amyloid A (SAA)
|
Protein
|
Humans
|
Downregulated with α2M deficiency (without α2M deficiency: 54.7±44.5 Vs with α2M deficiency: 2.15±1.68)
|
Prognostic
|
PCa patients without α2M deficiency vs. PCa patients with α2M deficiency
|
p<0.01
|
Serum
|
21894431
|
716
|
interleukin-6 (IL-6)
|
Protein
|
Humans
|
Downregulated with α2M deficiency (without α2M deficiency: 46.50±40.65 Vs with α2M deficiency: 3.38±2.61)
|
Prognostic
|
PCa patients without α2M deficiency vs. PCa patients with α2M deficiency
|
p<0.01
|
Serum
|
21894431
|
717
|
α1 anti-chymotripsin (α1AT)
|
Protein
|
Humans
|
Upregulated (Healthy: 122±28.0 Vs with α2M deficiency: 293.76±68.51)
|
Diagnostic
|
Healthy controls vs. PCa patients with α2M deficiency
|
p<0.05
|
Serum
|
21894431
|
718
|
α1 acid glycoprotein (α1AG)
|
Protein
|
Humans
|
Upregulated (Healthy: 67.5±25.5 Vs with α2M deficiency: 100.8±38.90)
|
Diagnostic
|
Healthy controls vs. PCa patients with α2M deficiency
|
p<0.05
|
Serum
|
21894431
|
719
|
Ceruloplasmin (CP)
|
Protein
|
Humans
|
Upregulated (Healthy: 29.0±8.0 Vs without α2M deficiency: 37.6±10.89)
|
Diagnostic
|
Healthy controls vs. PCa patients with α2M deficiency
|
p<0.05
|
Serum
|
21894431
|
763
|
tPSA
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (PCA: Median: 7.51; BPH: Median: 4.15)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Serum
|
21963599
|
775
|
Vitamin -C
|
Protein
|
Humans
|
Downregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Serum
|
21993000
|
776
|
Vitamin -E
|
Protein
|
Humans
|
Downregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Serum
|
21993000
|
778
|
Vitamin -C
|
Protein
|
Humans
|
Downregulated in Localised and Bone Metastasis
|
Prognostic
|
Controls Vs Localised Vs Bone Metastasis
|
p<0.05
|
Serum
|
21993000
|
779
|
Vitamin -E
|
Protein
|
Humans
|
Downregulated in Localised and Bone Metastasis
|
Prognostic
|
Controls Vs Localised Vs Bone Metastasis
|
p<0.05
|
Serum
|
21993000
|
781
|
Vitamin -C
|
Protein
|
Humans
|
Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.)
|
Prognostic
|
Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A)
|
p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A)
|
Serum
|
21993000
|
782
|
Vitamin -E
|
Protein
|
Humans
|
Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.)
|
Prognostic
|
Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A)
|
p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with no Treatment)
|
Serum
|
21993000
|
784
|
Vitamin -C
|
Protein
|
Humans
|
Upregulated in PCA (GS<7, GS=7, GS>7)
|
Prognostic
|
Controls Vs GS<7 Vs GS =7 Vs GS>8
|
p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7)
|
Serum
|
21993000
|
785
|
Vitamin -E
|
Protein
|
Humans
|
Upregulated in PCA (GS<7, GS=7, GS>7)
|
Prognostic
|
Controls Vs GS<7 Vs GS =7 Vs GS>9
|
p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7)
|
Serum
|
21993000
|
787
|
Auto-antibody profile (TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes)
|
Protein (Auto-antibodies)
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign disease
|
p<0.001
|
Serum
|
22012634
|
788
|
TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes
|
Protein (Auto-antibodies)
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p<0.001
|
Serum
|
22012634
|
789
|
tPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa VS Benign Prostatic Hyperplasia
|
p≤ 0.05
|
Serum
|
22024423
|
790
|
cPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa VS Benign Prostatic Hyperplasia
|
p≤ 0.05
|
Serum
|
22024423
|
791
|
f/tPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa VS Benign Prostatic Hyperplasia
|
p≤ 0.05
|
Serum
|
22024423
|
792
|
c/tPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa VS Benign Prostatic Hyperplasia
|
p≤ 0.05
|
Serum
|
22024423
|
793
|
Cholesterol
|
Lipid
|
Humans
|
Upregulated in Fish Oil Diet
|
Predictive
|
Change in Western Diet VS Change in Fish Oil Diet in Patients with PCa
|
0.005
|
Serum
|
22027686
|
794
|
Triglycerides
|
Lipid
|
Humans
|
Upregulated in Fish Oil Diet
|
Predictive
|
Change in Western Diet VS Change in Fish Oil Diet in Patients with PCa
|
p < 0.001
|
Serum
|
22027686
|
795
|
mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-215; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887
|
miRNA
|
Mice
|
Upregulated: [mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887]; Downregulated: [mmu-mir-215]
|
Diagnostic
|
TRAMP and wild-type (WT) littermate control mice
|
p≤ 0.05
|
Serum
|
22052531
|
796
|
hsa-mir-141; hsa-mir-298; hsa-mir-375
|
miRNA
|
Humans
|
Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-375]
|
Diagnostic
|
Normal Vs Primary Tumor
|
p≤ 0.05
|
Serum
|
22052531
|
797
|
hsa-mir-141; hsa-mir-298; hsa-mir-346; hsa-mir-375
|
miRNA
|
Humans
|
Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-346 ; hsa-mir-375]
|
Diagnostic
|
Normal Vs Metastatic Tumor
|
p≤ 0.05
|
Serum
|
22052531
|
798
|
hsa-mir-375
|
miRNA
|
Humans
|
High expression associated with an increased risk of BCR
|
Prognostic
|
Biochemical Recurrenece
|
p = 0.002
|
Serum
|
22052531
|
799
|
hsa-mir-375
|
miRNA
|
Humans
|
High expression with reduced chances of relapse free survival
|
Prognostic
|
Biochemical Recurrenece
|
Univariate: p=0.0001; Multivariate: p=0.0260
|
Serum
|
22052531
|
817
|
Interleukin-18 (IL-18)
|
Protein
|
Humans
|
Upregulated in BPH and Prostate cancer: [ Controls: 143.97 ± 2.29; BPH: 145.88 ± 1.93; TNM Stage 2: 229.54 ± 3.30; TNM Stage 3: 245.66 ± 4.05; TNM Stage 4: 251.64 ± 4.12]
|
Prognostic
|
Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage
|
p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4]
|
Serum
|
22126577
|
818
|
Interleukin-10 (IL-10)
|
Protein
|
Humans
|
Upregulated in BPH and Prostate cancer: [ Controls: 2.08 ± 0.27; BPH: 2.15 ± 0.18; TNM Stage 2: 8.03 ± 0.49; TNM Stage 3: 13.06 ± 0.45; TNM Stage 4: 6.32 ± 0.29]
|
Prognostic
|
Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage
|
p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4]
|
Serum
|
22126577
|
819
|
Interleukin-18 (IL-18)
|
Protein
|
Humans
|
Increased expression in patients with poor survival
|
Prognostic
|
Survival Vs No Survival
|
p<0.001
|
Serum
|
22126577
|
820
|
Interleukin-10 (IL-10)
|
Protein
|
Humans
|
Increased expression in patients with poor survival
|
Prognostic
|
Survival Vs No Survival
|
p<0.001
|
Serum
|
22126577
|
827
|
Auto-antibody signature (TARDBP, TLN1, PARK7, LEDGF/ PSIP1, and CALD1)
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
p< 0.05
|
Serum
|
22146597
|
828
|
TARDBP; TLN1; ;PARK7; LEDGF/PSIP1; CALD1; p73; PTEN; PXN; PEX10; KLK3; DBN1; NFAT1; B Tubulin; SOS1; HSF4; TOP1; HSPA1A/B;
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
p< 0.05
|
Serum
|
22146597
|
831
|
sPLA2-IIA (Secreted group IIA phospholipase A2)
|
Protein
|
Humans
|
Upregulated in Prostate cancer
|
Diagnostic
|
Controls Vs Prostate Cancer
|
p<0.001
|
Serum
|
22189868
|
832
|
CRP (C- Reactive Protein)
|
Protein
|
Humans
|
Upregulated in Prostate cancer
|
Diagnostic
|
Controls Vs Prostate Cancer
|
p<0.001
|
Serum
|
22189868
|
868
|
Alpha2- macroglobin (α2m); Elongation Factor 1A (EFA1) ; Lumican ; Complement Factor 1 Light Chain; Heparin Cofactor 2; Inter-alpha-trypsin inhbitor heavy chain H2; Serum amyloid P-component; Histidine Rich gylcoprotien; Transthyretin
|
Protein
|
Humans
|
Upregulated: [Alpha2- macroglobin (α2m) (1.4 fold); Elongation Factor 1A (EFA1) (1.2 fold); Lumican (1.1 fold); Downregulated: [Complement Factor 1 Light Chain (1.1 fold); Heparin Cofactor 2 (1.1 fold) ; Inter-alpha-trypsin inhbitor heavy chain H2 (1.1 fold) ; Serum amyloid P-component (1.1 fold); Histidine Rich gylcoprotien (1.3 fold) ; Transthyretin (1.4 fold)]
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
869
|
Beta-2-gylcoprotien 1 + Somatomedin- B
|
Protein
|
Humans
|
Upregulated: [Beta-2-gylcoprotien 1 (1.2 fold)+ Somatomedin- B (1.1 fold)]
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
870
|
Antithrombin III + Inter-alpha-trypsin inhibitor heavy chain H3
|
Protein
|
Humans
|
Downregulated: [Antithrombin III (1.4 fold)+ Inter-alpha-trypsin inhibitor heavy chain H3 (1.7 fold)]
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
871
|
Afamin + Fibronectin 1 + Alpha-2-HS-glycoprotien chain B
|
Protein
|
Humans
|
Upregulated : [Afamin (1.4 fold) + Fibronectin 1 (1.4 fold) + Alpha-2-HS-glycoprotien chain B (1.1 fold)]
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
872
|
cDNA FLJ55673 + cDNA FLJ58564 + Ceruplasmin + Complement C5 + Alpha-1-antichymotrypsin + Complement component C9b + cDNA FLJ54228
|
Protein
|
Humans
|
Downregulated : [cDNA FLJ55673 (1.1 fold)+ cDNA FLJ58564 (1.1 fold)+ Ceruplasmin (1.1 fold) + Complement C5 (1.1 fold) + Alpha-1-antichymotrypsin (1.2 fold) + Complement component C9b (1.2 fold) + cDNA FLJ54228 (1.5 fold)
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
873
|
cDNA FLJ51403 ; Elongation Factor 1A (EF-A1) ; Alpha 1B - glycoprotien; Complement component C7; Inter-alpha (Globulin) inhibitor H4; Kininogen 1; Plasma retinol-binding protien; cDNA FLJ77744; Complement C1r subcomponent-like Protein; Ficolin-3
|
Protein
|
Humans
|
Upregulated: [cDNA FLJ51403 (1.9 fold); Elongation Factor 1A (EF-A1) (1.8 fold); Alpha 1B - glycoprotien (1.1 fold) ; Complement component C7 (1.1 fold) ; Inter-alpha (Globulin) inhibitor H4;(1.1 fold)]; Downregulated: [Kininogen 1 (1.1 fold); Plasma retinol-binding protien (1.2 fold); cDNA FLJ77744 (1.4 fold); Complement C1r subcomponent-like Protein (1.4 fold); Ficolin-3 (1.4 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
874
|
Inter-alpha-trypsin inhibitor heavy chain H3 + Antithrombin III
|
Protein
|
Humans
|
Upregulated [Inter-alpha-trypsin inhibitor heavy chain H3 (2.0 fold) + Antithrombin III (1.2 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
875
|
Apliopoprotien A-IV + Complement Component 4B
|
Protein
|
Humans
|
Downregulated [Apliopoprotien A-IV (1.1 fold)+ Complement Component 4B (1.3 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
876
|
Beta 2-Glycoprotein 1 + Somatomedin- B
|
Protein
|
Humans
|
Downregulated [Beta 2-Glycoprotien 1 (1.1 fold) + Somatomedin- B (1.2 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
877
|
Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1
|
Protein
|
Humans
|
Downregulated [Alpha-2 HS-glycoprotien chain B (1.2 fold) + Afamin (1.5 fold)+ Fibronectin 1 (1.6 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
878
|
Elongation Factor 1A (EFA1) ; Zinc-alpha-2-glycoprotien ; Complement Compnent C6; Hemopexin ; Vitamin D-binding protien; cDNA FLJ53698; Histidine-rich glycoprotien; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; N-acetlymuramoyl-L-alanine amidase; Thyroxine-binding globulin
|
Protein
|
Humans
|
Upregulated [Elongation Factor 1A (EFA1) (1.4 fold) ; Zinc-alpha-2-glycoprotien (1.3 fold) ; Complement Compnent C6 (1.2 fold); Hemopexin (1.2 fold); Vitamin D-binding protien (1.1 fold)];Downregulated [cDNA FLJ53698 (1.3 fold); Histidine-rich glycoprotien (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H1 (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H2 (1.4 fold); N-acetlymuramoyl-L-alanine amidase (1.4 fold); Thyroxine-binding globulin (1.5 fold)]
|
Prognostic
|
Progressing Vs Metastatic Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
879
|
Apliopoprotien A-IV + Complement Component 4B
|
Protein
|
Humans
|
Upregulated [Apliopoprotien A-IV (1.3 fold) + Complement Component 4B (1.4 fold)]
|
Prognostic
|
Progressing Vs Metastatic Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
880
|
Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1
|
Protein
|
Humans
|
Downregulated [Alpha-2 HS-glycoprotien chain B (1.9 fold) + Afamin (1.9 fold)+ Fibronectin 1 (2.1 fold)]
|
Prognostic
|
Progressing Vs Metastatic Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
881
|
cDNA FLJ54228 + Alpha-1-antichymotrypsin+ Complement component C9b+ cDNA FLJ58564 + Complement C5+Ceruloplasmin+cDNA FLJ55673
|
Protein
|
Humans
|
Upregulated [cDNA FLJ54228 (2.2 fold)+ Alpha-1-antichymotrypsin (1.8 fold)+ Complement component C9b (1.4 fold)+ cDNA FLJ58564 (1.3 fold) + Complement C5 (1.3 fold) +Ceruloplasmin (1.2 fold) +cDNA FLJ55673 (1.1 fold)]
|
Prognostic
|
Progressing Vs Metastatic Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
897
|
Macroglobulin α2 ; HP protein; CLU precursor; Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region;
|
Protein
|
Humans
|
Upregulated [>1.5 fold]: (Macroglobulin α2 ; HP protein; CLU precursor; ) Downregulated: [1.5 fold] (Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region;)
|
Predictive
|
Before and after androgen ablation therapy (AAT)
|
p<0.01
|
Serum
|
22496929
|
898
|
Transthyretin (TTR)
|
Protein
|
Humans
|
Downregulated (1.58 fold ) in Post AAT patients
|
Predictive
|
Before and after androgen ablation therapy (AAT)
|
p<0.01
|
Serum
|
22496929
|
899
|
Clusterin (CLU)
|
Protein
|
Humans
|
Upregulated (1.51 fold ) in Post AAT patients
|
Predictive
|
Before and after androgen ablation therapy (AAT)
|
p<0.01
|
Serum
|
22496929
|
902
|
(Table 1)
|
Protein
|
Humans
|
Upregulated in PCa [1.12-2.25]
|
Diagnostic
|
Patients Vs Controls
|
p<0.05
|
Serum
|
22499197
|
907
|
%p2PSA
|
Protein
|
Humans
|
Upreregulated in PCa
|
Diagnostic
|
PCa VS No PCa group; PCa Vs HGPIN group
|
p<0.001
|
Serum
|
22542564
|
908
|
(percent free PSA) % fPSA
|
Protein
|
Humans
|
Downregulated in PCa [No PCa: 19.36 ; PCa: 15.41; HGPIN: 22.23]
|
Diagnostic
|
PCa VS No PCa group; PCa Vs HGPIN group
|
No PCa Vs PCa:p=0.004; PCa Vs HGPIN: p<0.001
|
Serum
|
22542564
|
909
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upreregulated in PCa
|
Diagnostic
|
PCa VS No PCa group; PCa Vs HGPIN group
|
p< 0.001
|
Serum
|
22542564
|
929
|
Spondin-2 (SPON2)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p=0.001
|
Serum
|
22615945
|
930
|
Triosephosphate isomerase 1 (TPI1); Spondin-2 (SPON-2); Thrombospondin 1, N-Terminal Domain (THBS1); Phosphoglycerate mutase 1 (PGAM1); Syndecan binding protein 1 (ST1); Peroxiredoxin 1 (PRDX1); Nucleophosmin- isoform CRA_c (NPM1)
|
Protein
|
Cell Lines
|
Differentially Expressed in PCA
|
Diagnostic
|
BPH-1, LNCaP Vs C4-2
|
p<0.05
|
Serum
|
22615945
|
940
|
Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR)
|
Protein
|
Humans
|
Downregulated in PCa [Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); ] Upregulated in PCa [Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR)]
|
Diagnostic
|
Benign Prostatic Hyperplasia (BPH) Vs Prostate Cancer (PCa)
|
p<0.01
|
Serum
|
22740474
|
961
|
Prostate health index (phi)
|
Protein
|
Humans
|
Upregulated in PCa [No PCa: 36.84 (28.82–46.14) Vs PCa 49.97 (37.75–69.65)]
|
Diagnostic
|
PCa Vs No-PCa
|
<0.001
|
Serum
|
22821756
|
963
|
PCA3 + phi
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No-PCa
|
p=0.001
|
Urine + Serum
|
22821756
|
964
|
Soluble interleukin-6 Receptor (sIL-6R)
|
Protein
|
Humans
|
Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 65.62±23.87 Vs With Gleason Score Upgrading: 94.63±33.31)
|
Prognostic
|
Gleason Score Upgrading Vs No Gleason Score Uprading
|
p=0.024
|
Serum
|
22866141
|
965
|
Soluble interleukin-6 Receptor / Interleukin-6 ((sIL-6R/IL-6)
|
Protein
|
Humans
|
Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 9.23±5.78 Vs With Gleason Score Upgrading: 15.61±4.94)
|
Prognostic
|
Gleason Score Upgrading Vs No Gleason Score Uprading
|
p=0.011
|
Serum
|
22866141
|
966
|
Osteopontin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs Controls (Healthy Donors + BPH)
|
p<0.05
|
Serum
|
22870138
|
969
|
hsa-miR-375; hsa-miR-96; hsa-miR-892b; hsa-miR-378; hsa-miR-302b; hsa-miR-548c-3p; hsa-miR-124; hsa-miR-141; hsa-miR-875-5p; hsa-miR-409-3p; hsa-miR-548a-3p; hsa-miR-623; hsa-miR-520d-5p; hsa-miR-489
|
miRNA
|
Humans
|
Upregulated in PCa: [hsa-miR-375 (8 fold); hsa-miR-96 (45.3 fold); hsa-miR-892b (9.9 fold); hsa-miR-378 (9.2 fold); hsa-miR-302b (45.3 fold); hsa-miR-548c-3p (2.8 fold); hsa-miR-124 (4.6 fold); hsa-miR-141 (6.5 fold); hsa-miR-875-5p (4.6 fold) ;hsa-miR-548a-3p (2.8 fold); hsa-miR-520d-5p (2.6 fold); hsa-miR-489 (7.5 fold)]; Downregulated in PCa: [ hsa-miR-409-3p (7 fold); hsa-miR-623 (2.6 fold); ]
|
Prognostic
|
LowRisk(LR) Vs Metastatic CRPC
|
p<0.0001
|
Serum
|
22887127
|
972
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Downregulated with Increased BMI: [BMI <23: 9.49±3.46 Vs BMI >25: 6.28±1.36]
|
Prognostic
|
BMI Group <23 Vs BMI Group >25
|
p=0.001
|
Serum
|
22901185
|
973
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa [Patients: 7.8±3; Controls: 1.9±0.98]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.001
|
Serum
|
22901185
|
974
|
ACP
|
Protein
|
Humans
|
Upregulated in PCa [Patients: 4.8±1.8; Controls: 3.1±0.6]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.001
|
Serum
|
22901185
|
975
|
PAP
|
Protein
|
Humans
|
Upregulated in PCa [Patients: 2.0±1.7 Controls: 0.5±0.2]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.001
|
Serum
|
22901185
|
989
|
Zinc α2-glycoprotein (ZAG) + PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA VS No PCA group
|
p=0.05
|
Urine + Serum
|
23020913
|
1013
|
Survivn
|
Protein
|
Humans
|
Upregulated in PCA (150 pg/ml ) compared to both Healthy controls (59.7 pg/ml) and BPH (55 pg/ml)
|
Diagnostic
|
(Normal and BPH )VS PCa
|
p<0.001
|
Serum
|
23091600
|
1024
|
Serum PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
PCa Vs No PCA group
|
p<0.001
|
Serum
|
23201468
|
1025
|
Serum PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
Gleason Score <7 Vs Gleason score ≥ 7
|
p = 0.003
|
Serum
|
23201468
|
1026
|
Serum PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
Tumor Stage (T3-T4)
|
p = 0.002
|
Serum
|
23201468
|
1032
|
C-terminal telopeptide
|
Protein
|
Humans
|
Downregulated in patients with PCa treated with with Risedronate (Placebo: 138.16± 26.71; Risedronate: 18.24 ± 22.38)
|
Predictive
|
Placebo vs Risedronate (after 24 months)
|
p =0.0014
|
Serum
|
23265571
|
1033
|
Bone-specific alkaline phosphatase
|
Protein
|
Humans
|
Downregulated in patients with PCa treated with with Risedronate (Placebo: 60.29 ± 10.28; Risedronate: 9.94 ± 6.95)
|
Predictive
|
Placebo vs Risedronate (after 24 months)
|
p =0.0002
|
Serum
|
23265571
|
1034
|
N-Mid-Osteocalcin
|
Protein
|
Humans
|
Downregulated in patients with PCa treated with with Risedronate (Placebo: 100.35 ± 30.4; Risedronate: 18.85 ± 10.8)
|
Predictive
|
Placebo vs Risedronate (after 24 months)
|
p =0.0173
|
Serum
|
23265571
|
1035
|
BMI1
|
Protein
|
Humans
|
Upregulated with Advanced Stage PCa (stage 2: 3.91±.60 Vs Stage 3: 8.55 ±1.95; Stage 4: 10.84 ± 2.44)
|
Prognostic
|
Stage 2 Vs Stage 3 Vs Stage 4 Prostate Cancer
|
p< 0.001
|
Serum
|
23308129
|
1047
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Serum
|
23356551
|
1054
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.001
|
Serum
|
23356551
|
1057
|
Testosterone
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 4.62 ±1.48; After: 0.15 ± 0.1)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1058
|
Dihydrotestosterone (DHT)
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 0.88 ±0.41 ; After: 0.05 ± 012)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1059
|
Dehydroepiandrosterone sulfate (DHEA-S)
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 133.3 ±63.8; After: 83.4 ± 51.4)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1060
|
Androstenedione
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 1.6 ±0.61 ; After: 0.83 ± 0.42)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1061
|
3α-diol-G
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 26.4 ±6.9 ; After: 5.4 ± 7.1)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1062
|
Insulin-like growth factor 1 (IGF-I)
|
Metabolites
|
Humans
|
Upregulated with Androgen Deprivation Therapy (Before: 19.9 ±7.7 ; After: 22.2 ±9.1 )
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p=0.001
|
Serum
|
23374809
|
1063
|
1,25(OH)2D
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 66.2 ±4.2 ; After: 59.7 ± 4.0)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p=0.008
|
Serum
|
23374809
|
1064
|
miR-141
|
miRNA
|
Humans
|
Upregulated in Bone Metastasis
|
Prognostic
|
Patients with Bone Metastasis Vs No Bone Metastasis
|
p<0.001
|
Serum
|
23377530
|
1103
|
Apolipoprotein B
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.01
|
Serum
|
23582881
|
1104
|
Biotinidase
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.041
|
Serum
|
23582881
|
1105
|
Cell adhesion molecule 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.046
|
Serum
|
23582881
|
1106
|
Complement factor H
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.025
|
Serum
|
23582881
|
1107
|
Ceruloplasmin
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.041
|
Serum
|
23582881
|
1108
|
Carboxypeptidase M
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.001
|
Serum
|
23582881
|
1109
|
Intercellular adhesion molecule 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.041
|
Serum
|
23582881
|
1110
|
Galectin-3-binding protein
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.009
|
Serum
|
23582881
|
1111
|
Serum paraoxonase/arylesterase 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.011
|
Serum
|
23582881
|
1112
|
Poliovirus receptor-related protein 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.046
|
Serum
|
23582881
|
1113
|
Thrombospondin-1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.022
|
Serum
|
23582881
|
1114
|
Transmembrane 9 superfamily member 3
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.037
|
Serum
|
23582881
|
1123
|
miR-24
|
miRNA
|
Mice
|
Upregulated in TRAMP Mice
|
Diagnostic
|
TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) VS Wild Type (WT) mice
|
p < 0.01
|
Serum
|
23719956
|
1124
|
β-CTX (β-isomer of carboxiterminal telopeptide of collagen I)
|
Protein
|
Humans
|
NA
|
Predictive
|
Survival Vs No Survival after treatment with zoledronic acid
|
p = 0.0049
|
Serum
|
23722472
|
1125
|
P1NP (aminoterminal propeptide of procollagen I)
|
Protein
|
Humans
|
NA
|
Predictive
|
Survival Vs No Survival after treatment with zoledronic acid
|
p = 0.0139
|
Serum
|
23722472
|
1148
|
C-Reactive Protein (CRP)
|
Protein
|
Humans
|
Higher levels associated with shorter biochemical failure-free survival (Both for patients with Post- radical Prostatectomy and Definitive Radiotherapy)
|
Prognostic
|
Biochemical Failure Free survival
|
p = 0.009
|
Serum
|
23818401
|
1149
|
Insulin Like Growth Factor Binding Proteins (IGFBP-3)
|
Protein
|
Humans
|
Upregulated in Intervention Group
|
Predictive
|
Intervention Vs Control Group
|
p = 0.002
|
Serum
|
23775525
|
1170
|
miR-141
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.007
|
Serum
|
23846169
|
1171
|
miR-146b-3p
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.008
|
Serum
|
23846169
|
1172
|
miR-194
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.044
|
Serum
|
23846169
|
1173
|
miR-146b-3p
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.02
|
Serum
|
23846169
|
1174
|
miR-194
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.029
|
Serum
|
23846169
|
1176
|
Prostate Health Index (phi)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No evidence of Maligancy
|
p <0.001
|
Serum
|
23861782
|
1198
|
Angiogenin
|
Protein
|
Humans
|
Upregulated in Patients with PCa (median): [Cancer 487,500 vs. Non Cancer: 414,800)
|
Diagnostic
|
Prostate Cancer Vs Non Cancer
|
p = 0.008
|
Serum
|
23921786
|
1199
|
miR-210
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 6.9 fold; Cohort 2: 3.1 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
p=0.022
|
Serum
|
23935962
|
1200
|
miR-141
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 27.9 fold; Cohort 2: 5.1 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Training: p<0.0001; Testing: p<0.001
|
Serum
|
23935962
|
1201
|
miR-200a
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 6.1 fold; Cohort 2: 1.76 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Training: p=0.007; Testing: p=NS
|
Serum
|
23935962
|
1202
|
miR-200c
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 22.4 fold; Cohort 2: 2.56 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Training: p=0.017; Testing: p=NS
|
Serum
|
23935962
|
1203
|
miR-375
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 4.6 fold; Cohort 2: 11.27 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Training: p=0.009; Testing: p=0.021
|
Serum
|
23935962
|
1219
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Serum
|
24086370
|
1232
|
N-terminal propeptide of collagen type I (PINP)
|
Protein
|
Humans
|
Upregulated in Bone Metastatis
|
Prognostic
|
Bone Metastatis Vs No Bone Metastatis
|
P < 0.001
|
Serum
|
24179387
|
1242
|
iXip: [IgM] + [tPSA]
|
Protein
|
Humans
|
Upregulated in PCa [PCa: 0.467 ± 0.160; Controls: 0.314 ± 0.098]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p <0.001
|
Serum
|
24240583
|
1321
|
miR-25; miR-101;miR-628-5p
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
African Americans Vs Caucasian Americans with PCa
|
p<0.05
|
Serum
|
24477576
|
1322
|
miR-25
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
African Americans Vs Caucasian Americans with PCa
|
p= 0.0109
|
Serum
|
24477576
|
1323
|
miR-101
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
African Americans Vs Caucasian Americans with PCa
|
p= 0.0006
|
Serum
|
24477576
|
1324
|
miR-628-5p
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
African Americans Vs Caucasian Americans with PCa
|
p<0.0001
|
Serum
|
24477576
|
1344
|
Bone Alkaline Phosphatase [BAP]
|
Protein
|
Humans
|
Upregulated (Estimate: 0.16)
|
Predictive
|
Atrasentan Vs Placebo Arm at baseline to week 9
|
p<0.001
|
Serum
|
24565955
|
1345
|
C-terminal of type 1 collagen [CICP]
|
Protein
|
Humans
|
Downregulated (Estimate: 0.16)
|
Predictive
|
Atrasentan Vs Placebo Arm at baseline to week 9
|
p<0.001
|
Serum
|
24565955
|
1346
|
Pyridinoline [PYD]
|
Protein
|
Humans
|
Downregulated (Estimate: 0.16)
|
Predictive
|
Atrasentan Vs Placebo Arm at baseline to week 9
|
p<0.001
|
Serum
|
24565955
|
1347
|
Bone Alkaline Phosphatase [BAP]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Serum
|
24565955
|
1348
|
C-terminal of type 1 collagen [CICP]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p <0.001
|
Serum
|
24565955
|
1349
|
Pyridinoline [PYD]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p <0.001
|
Serum
|
24565955
|
1350
|
N-telopeptides of type 1 collagen [NTx]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p <0.001
|
Serum
|
24565955
|
1420
|
Macrophage Colony Stimulating Factor (M-CSF)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1421
|
CC chemokine ligand 18 (CCL-18)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1422
|
Insulin-Like Growth Factor-Binding Protein 6 (IGFBP-6)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1423
|
Ttumor Necrosis Factor Receptor Superfamily Member 6 (TNFRSF6) [FAS/TNFRSF6]
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1454
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa: [Prostate Volume ≤ 35: Negative Biopsy: 41.32 (31.30–64.23), Positive Biopsy: 64.93 (23.30–252.76) 36 ≤ Prostate Volume ≤ 50 : Negative Biopsy: 35.38 (20.69–49.80), PCa: 44.56 (21.88–132.72);Prostate Volume >50: 38.34 (19.23–72.63), PCa: 46.28 (24.33–80.34)]
|
Diagnostic
|
Negative Vs PCa (Segregated on the basis of Prostate Volume)
|
Prostate Volume ≤ 35:p= 0.001;36 ≤ Prostate Volume ≤ 50 : p= 0.011;Prostate Volume >50: 0.009
|
Serum
|
24978824
|
1455
|
N-terminal telopeptide of type I collagen (NTx)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Gleason Score
|
p< 0.001
|
Serum
|
24992524
|
1456
|
N-terminal telopeptide of type I collagen (NTx)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Stage
|
p = 0.007
|
Serum
|
24992524
|
1458
|
Vascular Endothelial Growth Factor (VEGF)
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 356.3±181.1; BPH: 147.5±80; Healthy: 124.9±50.8)
|
Diagnostic
|
Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals)
|
p<0.001
|
Serum
|
25032132
|
1459
|
Vascular Endothelial Growth Factor (VEGF) + Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa: [VEGF+ PSA]
|
Diagnostic
|
Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals)
|
NA
|
Serum
|
25032132
|
1501
|
tPSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1502
|
p2PSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1503
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1504
|
Prostate Health Index (PHI)
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1505
|
tPSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1506
|
p2PSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1507
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1508
|
Prostate Health Index (PHI)
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1519
|
Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]
|
Protein
|
Humans
|
Upregulated 4K Score in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
PSA >3ng/ml: p<0.01; All Patients: p<0.04
|
Serum
|
25168616
|
1520
|
PCA3
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
PSA >3ng/ml: p=0.01; All Patients: p<0.01
|
Serum
|
25168616
|
1521
|
Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]+ PCA3
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
NA
|
Serum
|
25168616
|
1534
|
miRNA-21
|
miRNA
|
Humans
|
Upregulated in PCa( BPH: 1.3 ± 3.6; PCa:4.5 ± 3.6)
|
Diagnostic
|
Prostata Cancer Vs Benign prostatic hyperplasia
|
p=0.003
|
Serum
|
25190021
|
1535
|
miRNA-221
|
miRNA
|
Humans
|
Upregulated in PCa( BPH: 1.2 ± 2.5; PCa: 6.9±4.6)
|
Diagnostic
|
Prostata Cancer Vs Benign prostatic hyperplasia
|
p=0.004
|
Serum
|
25190021
|
1595
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa [BPH: 7.2 (1.8-19.8); PCa: 7.7 (1.0-19.4)]
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p = 0.0407
|
Serum
|
26254378
|
1596
|
%fPSA
|
Protein
|
Humans
|
Downregulated in PCa [BPH: 16.7 (1.8-45.4); PCa:11.7 (4.1-31.7)]
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.0001
|
Serum
|
26254378
|
1597
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa [BPH: 35.1 (13.1-155.6); PCa:61.6 (17.0-231.8)]
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.0001
|
Serum
|
26254378
|
1598
|
−2proPSA
|
Protein
|
Humans
|
Upregulated in PCa [BPH: 16.0 (3.0-81.0); PCa: 21.0 (4.0-135.0)]
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p = 0.0004
|
Serum
|
26254378
|
1666
|
tPSA
|
Protein
|
Humans
|
Upregulated in PCa Cell Lines
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1667
|
%fPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1668
|
p2PSA
|
Protein
|
Humans
|
Downregulated in Primary and Metastatic PCa
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1669
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 6.7; No PCa: 6.01)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1670
|
PHI (Prostate Health Index)
|
Protein
|
Humans
|
Downregulated in PCa (PCa in %: 13.5; No PCa in %: 17.6)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1671
|
tPSA + fPSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 14.92; No PCa: 11.79)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1672
|
tPSA + %fPSA
|
Protein
|
Humans
|
Downregulated in PCa (PCa in %: 20.5 ; No PCa in %: 15.5)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1673
|
fPSA + p2PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 48.62; No PCa: 33.35)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1674
|
%fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1675
|
PSA + %fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1676
|
tPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1677
|
fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1678
|
p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1679
|
%fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1680
|
%p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1681
|
PHI
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1682
|
tPSA+ fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1683
|
tPSA+ %fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1684
|
fPSA + p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1685
|
%fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1686
|
PSA + %fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1687
|
TIMP1 (Tissue Inhibitor Of Metalloproteinase 1)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p=0.003
|
Serum
|
25967040
|
1688
|
sE-Cadherin
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25967040
|
1689
|
Clusterin
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p=0.004
|
Serum
|
25967040
|
1690
|
MMP9
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25967040
|
1691
|
Galectin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No PCa
|
p=0.01
|
Serum
|
25967040
|
1692
|
sE-Cadherin
|
Protein
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Gleason Pattern 3 Vs 4 Vs 5
|
p=0.02
|
Serum
|
25967040
|
1693
|
sE-Cadherin
|
Protein
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Gleason Upgrade Vs No Gleason Upgrade
|
p=0.03
|
Serum
|
25967040
|
1704
|
hsv1-miR-H18
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue, Urine: p<0.001; Serum: p=0.004
|
Tissue+Urine+Serum
|
26126436
|
1705
|
hsv2-miR-H9-5p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue, Urine: p<0.001; Serum: p=0.002
|
Tissue+Urine+Serum
|
26126436
|
1706
|
hsa-miR-615-3p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001;
|
Tissue+Urine+Serum
|
26126436
|
1707
|
hsa-miR-BARTA-4
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue, Serum, Urine)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001;
|
Tissue+Urine+Serum
|
26126436
|
1708
|
hsa-miR-4316
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue, Serum, Urine)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001; Urine: p=0.022
|
Tissue+Urine+Serum
|
26126436
|
1723
|
Zn/PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.0001
|
Serum
|
30672309
|
1726
|
HA: Hyaluronic acid
|
Metabolites
|
Humans
|
Upregulated in PCa (PCa: 239.6 (145.1–357.7); No PCa: 150.8 (51.8–264.1))
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.004
|
Serum
|
30516927
|
1727
|
HA: Hyaluronic acid
|
Metabolites
|
Humans
|
NA
|
Prognostic
|
High Risk Vs Intermediate Risk PCa
|
p=0.0214
|
Serum
|
30516927
|
1728
|
HA: Hyaluronic acid
|
Metabolites
|
Humans
|
Upregulated in Patient Reclassification
|
Predictive
|
Before and After Surgery Levels
|
p=0.029
|
Serum
|
30516927
|
1751
|
Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine
|
Lipid
|
Humans
|
Upregulated in PCa: Fold change mean(BPH: 1.365; PCa: 10.108)
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
NA
|
Serum
|
30758971
|
1752
|
Gleason score+age,+pre-operative PSA +pathological stage+Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine
|
Lipid
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
NA
|
Serum
|
30758971
|
1761
|
CGA (chromogranin A)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.0416
|
Serum
|
30286478
|
1762
|
miR-1825
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1763
|
miR-484
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1764
|
miR-205
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1765
|
miR-141
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1766
|
let-7b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1767
|
miR-1825
|
miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Stage T1-T2 Vs Stage T3-T4
|
p<0.05
|
Serum
|
30324582
|
1768
|
let-7b
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Stage T1-T2 Vs Stage T3-T4
|
p<0.05
|
Serum
|
30324582
|
1769
|
miR-205
|
miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Bone Metastasis Vs No Bone Metastasis
|
p<0.05
|
Serum
|
30324582
|
1811
|
PHI (Prostate Health Index)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Serum
|
30926382
|
1812
|
PHID (Prostate Health Index Density)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Serum
|
30926382
|
1879
|
Testosterone
|
Protein
|
Humans
|
Decreased in Biochemical Recurrence Free Survival
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.037
|
Serum
|
30446464
|
1880
|
Testosterone
|
Protein
|
Humans
|
Decreased in Biochemical Recurrence Free Survival
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.0028
|
Serum
|
30446464
|
1881
|
Testosterone
|
Protein
|
Humans
|
Decreased in Biochemical Recurrence Free Survival
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.043
|
Serum
|
30446464
|
1882
|
Keratin, type II cytoskeletal 2 epidermal; Serum amyloid Pâ€component;Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 9; Isoform 2 of Filamin A; Isoform 3 of Vitamin Dâ€binding protein; Ig kappa chain Vâ€II region Cum; soform 2 of Eukaryotic translation initiation 1.8 factor 2â€alpha kinase 4; Ig alphaâ€1 chain C region; Afamin;
|
Protein
|
Humans
|
Increased in Progression Free survival
|
Diagnostic
|
Prostate Cancer in African American Men Vs Normal African American Men
|
p<0.05
|
Serum
|
30623593
|
1883
|
Complement component C8 alpha chain; Apolipoprotein Aâ€I; Plasminogen; Complement component C7;Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4;Interâ€alphaâ€trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain Vâ€III region BRO; Ig gammaâ€2 chain C region; Ig gammaâ€3 chain C region;
|
Protein
|
Humans
|
Decreased in Progression Free Survival
|
Diagnostic
|
Prostate Cancer in African American Men Vs Normal African American Men
|
p<0.05
|
Serum
|
30623593
|
1884
|
Complement component C8 alpha chain; Apolipoprotein Aâ€I; Plasminogen; Complement component C7;Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4;Interâ€alphaâ€trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain Vâ€III region BRO; Ig gammaâ€2 chain C region; Ig gammaâ€3 chain C region;
|
Protein
|
Humans
|
Decreased in Overall Survival
|
Diagnostic
|
Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men
|
p<0.05
|
Serum
|
30623593
|
1885
|
SCOâ€spondin; Complement component C7;Isoform 2 of Ankyrin repeat and SOCS box protein 18; Gelsolin; Serum amyloid Pâ€component; g heavy chain Vâ€I region V35; Complement C1q subcomponent subunit C; Complement component C8 alpha chain; Isoform 2 of Filamin A; Inter-alpha trypsin inhibitor heavy chain H2;
|
Protein
|
Humans
|
Upregulated in PCa (Keratin, type II cytoskeletal 2 epidermal (64 fold); Serum amyloid Pâ€component (39 fold) ;Keratin, type II cytoskeletal 1 (13 fod) ; Keratin, type I cytoskeletal 9 (12 fold) ; Isoform 2 of Filamin A (2.6 fold) ; Isoform 3 of Vitamin Dâ€binding protein (2.4 fold); Ig kappa chain Vâ€II region Cum (2.4 fold) ; Isoform 2 of Eukaryotic translation initiation 1.8 factor 2â€alpha kinase 4 (1.8 fold) ; Ig alphaâ€1 chain C region (1.7 fold) ; Afamin (1.5 fold);
|
Diagnostic
|
Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men
|
p<0.05
|
Serum
|
30623593
|
1886
|
Isoform 2 of Eukaryotic translation initiation factor 2â€alpha kinase 4; Keratin type I cytoskeletal 10; SCO†spondin; Serum amyloid Pâ€component; Apolipoprotein(a); Keratin, type I cytoskeletal 9; Ig kappa chain Vâ€IV region; Isoform 2 of Filamin A; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal;
|
Protein
|
Humans
|
Downregulated in PCa [Complement component C8 alpha chain (0.07 fold); Apolipoprotein Aâ€I (0.04 fold); Plasminogen (0.08 fold); Complement component C7 (0.1 fold); Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4 (0.2 fold); Interâ€alphaâ€trypsin inhibitor heavy chain H1 (0.2 fold); Complement C1s subcomponent (0.2 fold); Ig heavy chain Vâ€III region BRO (0.2 fold); Ig gammaâ€2 chain C region (0.2 fold); Ig gammaâ€3 chain C region (0.2 fold);]
|
Diagnostic
|
African American men with PCa (PAA) Vs Caucasian men with PCa (PCC)
|
p<0.05
|
Serum
|
30623593
|
1887
|
Ig heavy chain Vâ€III region BRO; Alphaâ€1â€antitrypsin; Plasminogen (0.1†fold); Ig heavy chain Vâ€III region TIL, Hemopexin; Afamin; Interâ€alphaâ€trypsin inhibitor heavy chain H1; Protein AMBP; Alphaâ€1Bâ€glycoprotein; Complement component C8 alpha chain;
|
Protein
|
Humans
|
Upregulated in PCa [Alphaâ€1â€acid glycoprotein 1 (13.6â€fold); Alphaâ€1Bâ€glycoprotein (11.6â€fold); von Willebrand factor (5.0â€fold); Ig heavy chain Vâ€II region NEWM (6.0â€fold); Ig heavy chain Vâ€III region BRO (5.7â€fold); Afamin (5.4â€fold); Apolipoprotein Aâ€I (4.9â€fold); Isoform 3 of Vitamin Dâ€binding protein (4.3â€fold); Complement C1r subcomponent (4.3†fold); Angiotensinogen (4.1â€fold);
|
Diagnostic
|
African American men with PCa (PAA) Vs Caucasian men with PCa (PCC)
|
p<0.05
|
Serum
|
30623593
|
1919
|
miR-17*
|
miRNA
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.040
|
Serum
|
25786615
|
1920
|
miR-200b*
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.045
|
Serum
|
25786615
|
1921
|
miR-210
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.003
|
Serum
|
25786615
|
1922
|
miR-297
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.27 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.031
|
Serum
|
25786615
|
1923
|
miR-375
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.13 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.009
|
Serum
|
25786615
|
1924
|
miR-501-3p
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.02 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.015
|
Serum
|
25786615
|
1925
|
miR-551b
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.30 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.017
|
Serum
|
25786615
|
1926
|
miR-562
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (14.66 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.01
|
Serum
|
25786615
|
1927
|
miR-562+ miR-210
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.12 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
NA
|
Serum
|
25786615
|
1928
|
miR-562+ miR-210+ miR-501-3p
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (17.39 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
NA
|
Serum
|
25786615
|
1929
|
miR-562+ miR-210+ miR-501-3p+ miR-375
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.72 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
NA
|
Serum
|
25786615
|
1930
|
miR-562+ miR-210+ miR-501-3p+ miR-375+ miR551b
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
NA
|
Serum
|
25786615
|
1931
|
let-7a*
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.012
|
Serum
|
25786615
|
1932
|
miR-200b*
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.028
|
Serum
|
25786615
|
1933
|
miR-210
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.01
|
Serum
|
25786615
|
1934
|
miR-297
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.038
|
Serum
|
25786615
|
1935
|
miR-375
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.014
|
Serum
|
25786615
|
1936
|
miR-501-3p
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.028
|
Serum
|
25786615
|
1937
|
miR-562
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.03
|
Serum
|
25786615
|
1938
|
miR-616
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.05
|
Serum
|
25786615
|
1939
|
let-7a*+ miR-210
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
NA
|
Serum
|
25786615
|
1940
|
let-7a*+ miR-210+ miR-562
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
NA
|
Serum
|
25786615
|
1941
|
let-7a*+ miR-210+ miR-562+ miR-616
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
NA
|
Serum
|
25786615
|
1942
|
let-7a*+ miR-210+ miR-562+ miR-616+ miR-297
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
NA
|
Serum
|
25786615
|